Ex vivo expansion of human T cells for adoptive immunotherapy using the novel Xeno-free CTS Immune Cell Serum Replacement.
AuthorsSmith C, Økern G, Rehan S, Beagley L, Lee SK, Aarvak T, Schjetne KW, Khanna R
Journal
PubMed ID25671129
The manufacture of clinical grade cellular products for adoptive immunotherapy requires ex vivo culture and expansion of human T cells. One of the key components in manufacturing of T cell therapies is human serum (HS) or fetal bovine serum (FBS), which can potentially expose immunotherapy recipient to adventitious infectious pathogens ... More
Bioengineering and serum free expansion of blood-derived ?d T cells.
AuthorsSutton KS, Dasgupta A, McCarty D, Doering CB, Spencer HT
JournalCytotherapy
PubMed ID27260209
'Cellular immunotherapy relies on several highly variable patient-specific parameters, such as (i) cell number before and after expansion, (ii) targeting of cells to tumors, (iii) cell survival and function after infusion, and (iv) on- and off-target adverse events. Cellular approaches such as the specific expansion of ?d T cells as ... More
A Rapid Cell Expansion Process for Production of Engineered Autologous CAR-T Cell Therapies.
AuthorsLu TL, Pugach O, Somerville R, Rosenberg SA, Kochendefer JN, Better M, Feldman SA
JournalHum Gene Ther Methods
PubMed ID27897048
The treatment of B-cell malignancies by adoptive cell transfer (ACT) of anti-CD19 chimeric antigen receptor T cells (CD19 CAR-T) has proven to be a highly successful therapeutic modality in several clinical trials.(1-6) The anti-CD19 CAR-T cell production method used to support initial trials relied on numerous manual, open process steps, ... More
Specific humoral and cellular immune responses in cancer patients undergoing chronic immunization with a VEGF-based therapeutic vaccine.
AuthorsMorera Y, Sánchez J, Bequet-Romero M, Selman-Housein KH, de la Torre A, Hernández-Bernal F, Martín Y, Garabito A, Piñero J, Bermúdez C, de la Torre J, Ayala M, Gavilondo JV
JournalVaccine
PubMed ID28536029
CIGB-247 is a cancer therapeutic vaccine, based on recombinant modified human vascular endothelial growth factor (VEGF) as antigen, in combination with the adjuvant VSSP, a bacterially-derived adjuvant. The vaccine have demonstrated efficacy in several murine malignancy models. These studies supported the rationale for a phase I clinical trial where safety, ... More
Enhancing adoptive cancer immunotherapy with V?2Vd2 T cells through pulse zoledronate stimulation.
AuthorsNada MH, Wang H, Workalemahu G, Tanaka Y, Morita CT
JournalJ Immunother Cancer
PubMed ID28239463
Human ?d T cells expressing V?2Vd2 T cell receptors monitor foreign- and self-prenyl pyrophosphate metabolites in isoprenoid biosynthesis to mediate immunity to microbes and tumors. Adoptive immunotherapy with V?2Vd2 T cells has been used to treat cancer patients with partial and complete remissions. Most clinical trials and preclinical studies have ... More